Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum
Primary Purpose
Lung Cancer, Tobacco Use Disorder
Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
defined green tea catechin extract
placebo
Sponsored by
About this trial
This is an interventional prevention trial for Lung Cancer focused on measuring non-small cell lung cancer, small cell lung cancer, tobacco use disorder
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Current smokers who have smoked at least 30 pack-years (e.g., 1 pack per day for 30 years or more) (part 1; completed March 22, 2006)
Former smokers who have smoked at least 30 pack-years (part 2)
- A former smoker is defined as one who has stopped smoking for one or more years
- Abnormal sputum score ≥ 0.25 by computer-assisted image analysis
- Exhaled carbon monoxide level < 5 ppm (part 2 )
- Willing to take defined green tea catechin extract/placebo twice a day regularly
No evidence of overt lung cancer
- No carcinoma in situ or invasive cancer on bronchoscopy or abnormal spiral chest CT suspicious of lung cancer
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-1
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Creatinine normal
- Bilirubin normal
- AST and ALT normal
- Alkaline phosphatase normal
Exclusion criteria:
- Chronic active hepatitis/liver cirrhosis
- Severe heart disease (e.g., unstable angina, chronic congestive heart failure, use of antiarrhythmic agents)
- Ongoing gastric ulcer
- Acute bronchitis or pneumonia within one month
- Known reaction to lidocaine, albuterol sulfate, midazolam hydrochloride, and/or alfentanil hydrochloride
- Known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients
- Any medical condition, such as acute or chronic respiratory failure or bleeding disorder that, in the opinion of the investigator, could jeopardize the patient's safety during participation in the study
- Unwilling to have a bronchoscopy
- Unwilling to have a spiral chest CT
PRIOR CONCURRENT THERAPY:
- No more than 5 cups of tea a week
- No concurrent anticoagulant treatment such as warfarin or heparin
- No use of other natural health products containing green tea compounds
Sites / Locations
- British Columbia Cancer Agency - Vancouver Cancer Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Arm I
Arm II
Arm Description
Patients receive oral defined green tea catechin extract twice daily for 6 months.
Patients receive oral placebo twice daily for 6 months.
Outcomes
Primary Outcome Measures
Changes in oncogene/tumor suppression gene expression (part 1; completed March 22, 2006)
Phase I and II enzyme regulation by Affymetrix chip analysis in bronchial brush cells (part 1)
C-reactive protein level in plasma before treatment and 1 and 2 months after treatment (part 1)
Quantitative sputum score by image analysis before and 6 months after treatment (part 2)
Secondary Outcome Measures
Change in pathology grade of bronchial biopsies (part 2)
Morphometric index of bronchial biopsies and bronchoalveolar lavage cells (BAL) (part 2)
Methylation markers in sputa and BAL cells (part 2)
Ki-67 expression (part 2)
Cleaved caspase 3, p53, and VEGF assays in bronchial biopsies (part 2)
Oncogene and tumor suppression gene expression (part 2)
Phase I and II enzyme regulation by Affymetrix chip analysis of RNA from bronchial brush cells (part 2)
C-reactive protein levels in plasma before treatment, and 6 months after treatment (part 2)
Resolution or progression of non-calcified lung nodules on spiral CT (part 2)
Full Information
NCT ID
NCT00573885
First Posted
December 13, 2007
Last Updated
March 7, 2012
Sponsor
British Columbia Cancer Agency
Collaborators
National Cancer Institute (NCI), University of Cincinnati
1. Study Identification
Unique Protocol Identification Number
NCT00573885
Brief Title
Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum
Official Title
Phase II Trial of Polyphenon E in Former Smokers With Abnormal Sputa
Study Type
Interventional
2. Study Status
Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
December 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
British Columbia Cancer Agency
Collaborators
National Cancer Institute (NCI), University of Cincinnati
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Green tea extract may keep cancer from forming.
PURPOSE: This randomized phase II trial is studying green tea extract in preventing cancer in former and current heavy smokers with abnormal sputum.
Detailed Description
OBJECTIVES:
Evaluate the efficacy and safety of defined green tea catechin extract (polyphenon E) in former smokers with abnormal sputum score using stringent, newly developed response criteria of combined nuclear morphometry and malignancy-associated changes as the primary surrogate endpoint.
Evaluate if polyphenon E can modulate other surrogate endpoint biomarkers of aberrant methylation, cell cycle regulation, apoptosis, oncogene/tumor suppressor gene expression, as well as phase I and II enzyme regulation.
Establish a library of in-vivo confocal micro-endoscopy and optical coherent tomography images of the bronchial epithelium with corresponding histopathology, nuclear morphometry, and other biomarker information to assess the potential of confocal micro-endoscopy as a non-biopsy method to assess the effect of chemoprevention agents.
OUTLINE: This is an open label, part 1 study followed by a randomized, double-blind, part 2 study.
Part 1 (completed March 22, 2006): Patients receive oral defined green tea catechin extract twice daily in months 1 and 2 and inhaled budesonide twice daily in month 2.
Patients undergo autofluorescence bronchoscopy with biopsies, oral and bronchial brushing, and bronchoalveolar lavage at the end of months 1 and 2.
Part 2: Patients are stratified by gender and randomized to 1 of 2 treatment arms.
Arm I: Patients receive oral defined green tea catechin extract twice daily for 6 months.
Arm II: Patients receive oral placebo twice daily for 6 months. Patients who have progressive or stable disease at 6 months may receive open-label defined green tea catechin extract.
Patients undergo autofluorescence bronchoscopy with biopsies, oral and bronchial brushing, and bronchoalveolar lavage at the end of months 6 and 12.
Blood samples are collected periodically for biomarker studies. After completion of study therapy, patients are followed periodically for 6 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Tobacco Use Disorder
Keywords
non-small cell lung cancer, small cell lung cancer, tobacco use disorder
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
53 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm I
Arm Type
Experimental
Arm Description
Patients receive oral defined green tea catechin extract twice daily for 6 months.
Arm Title
Arm II
Arm Type
Placebo Comparator
Arm Description
Patients receive oral placebo twice daily for 6 months.
Intervention Type
Drug
Intervention Name(s)
defined green tea catechin extract
Intervention Description
Given orally
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
Given orally
Primary Outcome Measure Information:
Title
Changes in oncogene/tumor suppression gene expression (part 1; completed March 22, 2006)
Time Frame
36 months
Title
Phase I and II enzyme regulation by Affymetrix chip analysis in bronchial brush cells (part 1)
Time Frame
60 months
Title
C-reactive protein level in plasma before treatment and 1 and 2 months after treatment (part 1)
Time Frame
60 months
Title
Quantitative sputum score by image analysis before and 6 months after treatment (part 2)
Time Frame
36 months
Secondary Outcome Measure Information:
Title
Change in pathology grade of bronchial biopsies (part 2)
Time Frame
36 months
Title
Morphometric index of bronchial biopsies and bronchoalveolar lavage cells (BAL) (part 2)
Time Frame
36 months
Title
Methylation markers in sputa and BAL cells (part 2)
Time Frame
60 months
Title
Ki-67 expression (part 2)
Time Frame
60 months
Title
Cleaved caspase 3, p53, and VEGF assays in bronchial biopsies (part 2)
Time Frame
60 months
Title
Oncogene and tumor suppression gene expression (part 2)
Time Frame
60 months
Title
Phase I and II enzyme regulation by Affymetrix chip analysis of RNA from bronchial brush cells (part 2)
Time Frame
60 months
Title
C-reactive protein levels in plasma before treatment, and 6 months after treatment (part 2)
Time Frame
36 months
Title
Resolution or progression of non-calcified lung nodules on spiral CT (part 2)
Time Frame
60 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS:
Current smokers who have smoked at least 30 pack-years (e.g., 1 pack per day for 30 years or more) (part 1; completed March 22, 2006)
Former smokers who have smoked at least 30 pack-years (part 2)
A former smoker is defined as one who has stopped smoking for one or more years
Abnormal sputum score ≥ 0.25 by computer-assisted image analysis
Exhaled carbon monoxide level < 5 ppm (part 2 )
Willing to take defined green tea catechin extract/placebo twice a day regularly
No evidence of overt lung cancer
No carcinoma in situ or invasive cancer on bronchoscopy or abnormal spiral chest CT suspicious of lung cancer
PATIENT CHARACTERISTICS:
Inclusion criteria:
ECOG performance status 0-1
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Creatinine normal
Bilirubin normal
AST and ALT normal
Alkaline phosphatase normal
Exclusion criteria:
Chronic active hepatitis/liver cirrhosis
Severe heart disease (e.g., unstable angina, chronic congestive heart failure, use of antiarrhythmic agents)
Ongoing gastric ulcer
Acute bronchitis or pneumonia within one month
Known reaction to lidocaine, albuterol sulfate, midazolam hydrochloride, and/or alfentanil hydrochloride
Known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients
Any medical condition, such as acute or chronic respiratory failure or bleeding disorder that, in the opinion of the investigator, could jeopardize the patient's safety during participation in the study
Unwilling to have a bronchoscopy
Unwilling to have a spiral chest CT
PRIOR CONCURRENT THERAPY:
No more than 5 cups of tea a week
No concurrent anticoagulant treatment such as warfarin or heparin
No use of other natural health products containing green tea compounds
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Lam, MD
Organizational Affiliation
British Columbia Cancer Agency
Official's Role
Study Chair
Facility Information:
Facility Name
British Columbia Cancer Agency - Vancouver Cancer Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum
We'll reach out to this number within 24 hrs